S&P 500   2,526.90 (+2.28%)
DOW   21,413.44 (+2.24%)
QQQ   186.01 (+2.03%)
AAPL   244.93 (+1.67%)
FB   158.19 (-0.88%)
MSFT   155.26 (+2.07%)
GOOGL   1,117.03 (+1.35%)
AMZN   1,918.83 (+0.58%)
CGC   13.80 (+1.62%)
NVDA   255.47 (+5.10%)
BABA   188.90 (+0.71%)
MU   41.09 (+3.01%)
GE   6.90 (-1.99%)
TSLA   454.47 (-5.63%)
AMD   44.49 (+1.90%)
T   28.76 (+2.53%)
ACB   0.83 (+2.46%)
F   4.36 (-0.91%)
NFLX   370.08 (+1.65%)
BAC   20.57 (+4.05%)
GILD   76.98 (+6.16%)
PRI   82.76 (-1.66%)
DIS   96.97 (+2.16%)
S&P 500   2,526.90 (+2.28%)
DOW   21,413.44 (+2.24%)
QQQ   186.01 (+2.03%)
AAPL   244.93 (+1.67%)
FB   158.19 (-0.88%)
MSFT   155.26 (+2.07%)
GOOGL   1,117.03 (+1.35%)
AMZN   1,918.83 (+0.58%)
CGC   13.80 (+1.62%)
NVDA   255.47 (+5.10%)
BABA   188.90 (+0.71%)
MU   41.09 (+3.01%)
GE   6.90 (-1.99%)
TSLA   454.47 (-5.63%)
AMD   44.49 (+1.90%)
T   28.76 (+2.53%)
ACB   0.83 (+2.46%)
F   4.36 (-0.91%)
NFLX   370.08 (+1.65%)
BAC   20.57 (+4.05%)
GILD   76.98 (+6.16%)
PRI   82.76 (-1.66%)
DIS   96.97 (+2.16%)
S&P 500   2,526.90 (+2.28%)
DOW   21,413.44 (+2.24%)
QQQ   186.01 (+2.03%)
AAPL   244.93 (+1.67%)
FB   158.19 (-0.88%)
MSFT   155.26 (+2.07%)
GOOGL   1,117.03 (+1.35%)
AMZN   1,918.83 (+0.58%)
CGC   13.80 (+1.62%)
NVDA   255.47 (+5.10%)
BABA   188.90 (+0.71%)
MU   41.09 (+3.01%)
GE   6.90 (-1.99%)
TSLA   454.47 (-5.63%)
AMD   44.49 (+1.90%)
T   28.76 (+2.53%)
ACB   0.83 (+2.46%)
F   4.36 (-0.91%)
NFLX   370.08 (+1.65%)
BAC   20.57 (+4.05%)
GILD   76.98 (+6.16%)
PRI   82.76 (-1.66%)
DIS   96.97 (+2.16%)
S&P 500   2,526.90 (+2.28%)
DOW   21,413.44 (+2.24%)
QQQ   186.01 (+2.03%)
AAPL   244.93 (+1.67%)
FB   158.19 (-0.88%)
MSFT   155.26 (+2.07%)
GOOGL   1,117.03 (+1.35%)
AMZN   1,918.83 (+0.58%)
CGC   13.80 (+1.62%)
NVDA   255.47 (+5.10%)
BABA   188.90 (+0.71%)
MU   41.09 (+3.01%)
GE   6.90 (-1.99%)
TSLA   454.47 (-5.63%)
AMD   44.49 (+1.90%)
T   28.76 (+2.53%)
ACB   0.83 (+2.46%)
F   4.36 (-0.91%)
NFLX   370.08 (+1.65%)
BAC   20.57 (+4.05%)
GILD   76.98 (+6.16%)
PRI   82.76 (-1.66%)
DIS   96.97 (+2.16%)
Log in

NASDAQ:SLRX - Salarius Pharmaceuticals Stock Price, Forecast & News

$0.64
-0.01 (-0.77 %)
(As of 04/2/2020 04:00 PM ET)
Today's Range
$0.64
Now: $0.65
$0.70
50-Day Range
$0.57
MA: $0.80
$1.04
52-Week Range
$0.56
Now: $0.65
$24.45
Volume40,300 shs
Average Volume294,906 shs
Market Capitalization$2.91 million
P/E RatioN/A
Dividend YieldN/A
Beta1.84
Salarius Pharmaceuticals, Inc. a clinical-stage oncology company, develops therapies for the treatment of patients with various cancers. The company's lead candidate is Seclidemstat, which is in clinical development for the treatment of Ewing sarcoma, as well as advanced solid tumors, including prostate, breast, and ovarian cancers. It has a collaborative partnership with The Ivy Brain Tumor Center at the Barrow Neurological Institute to to develop cancer treatment for glioblastoma. Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas.
Read More

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SLRX
CUSIPN/A
CIKN/A
Phone346-772-0346

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.46 million
Book Value$2.35 per share

Profitability

Net Income$-6,940,000.00
Net Margins-200.27%

Miscellaneous

Employees7
Market Cap$2.91 million
Next Earnings Date5/6/2020 (Estimated)
OptionableNot Optionable

Receive SLRX News and Ratings via Email

Sign-up to receive the latest news and ratings for SLRX and its competitors with MarketBeat's FREE daily newsletter.


Salarius Pharmaceuticals (NASDAQ:SLRX) Frequently Asked Questions

How has Salarius Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Salarius Pharmaceuticals' stock was trading at $0.7201 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SLRX shares have decreased by 10.4% and is now trading at $0.6450. View which stocks have been mosted impacted by Coronavirus.

When is Salarius Pharmaceuticals' next earnings date?

Salarius Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 6th 2020. View our earnings forecast for Salarius Pharmaceuticals.

Has Salarius Pharmaceuticals been receiving favorable news coverage?

Media stories about SLRX stock have trended very negative on Thursday, according to InfoTrie Sentiment. The research group identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Salarius Pharmaceuticals earned a daily sentiment score of -3.3 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news aboutSalarius Pharmaceuticals.

Who are some of Salarius Pharmaceuticals' key competitors?

What other stocks do shareholders of Salarius Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Salarius Pharmaceuticals investors own include Exxon Mobil (XOM), Aimmune Therapeutics (AIMT), Amarin (AMRN), Aurinia Pharmaceuticals (AUPH), Clovis Oncology (CLVS), Guardant Health (GH), Intra-Cellular Therapies (ITCI), Nektar Therapeutics (NKTR), Myovant Sciences (MYOV) and ADMA Biologics (ADMA).

Who are Salarius Pharmaceuticals' key executives?

Salarius Pharmaceuticals' management team includes the following people:
  • Mr. David J. Arthur, CEO, Pres & Director (Age 56)
  • Mr. Mark J. Rosenblum, Exec. VP of Fin. & Interim CFO (Age 66)
  • Mr. Sunil Sharma M.D., Chief Medical Officer
  • Mr. Scott Jordan, Chief Bus. Officer (Age 52)

What is Salarius Pharmaceuticals' stock symbol?

Salarius Pharmaceuticals trades on the NASDAQ under the ticker symbol "SLRX."

How do I buy shares of Salarius Pharmaceuticals?

Shares of SLRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Salarius Pharmaceuticals' stock price today?

One share of SLRX stock can currently be purchased for approximately $0.65.

How big of a company is Salarius Pharmaceuticals?

Salarius Pharmaceuticals has a market capitalization of $2.91 million and generates $3.46 million in revenue each year. The company earns $-6,940,000.00 in net income (profit) each year or ($2.12) on an earnings per share basis. Salarius Pharmaceuticals employs 7 workers across the globe. View additional information about Salarius Pharmaceuticals.

What is Salarius Pharmaceuticals' official website?

The official website for Salarius Pharmaceuticals is http://www.salariuspharma.com/.

How can I contact Salarius Pharmaceuticals?

Salarius Pharmaceuticals' mailing address is 2450 HOLCOMBE BLVD SUITE J-608, HOUSTON TX, 77021. The company can be reached via phone at 346-772-0346 or via email at [email protected]


MarketBeat Community Rating for Salarius Pharmaceuticals (NASDAQ SLRX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  10 (Vote Outperform)
Underperform Votes:  9 (Vote Underperform)
Total Votes:  19
MarketBeat's community ratings are surveys of what our community members think about Salarius Pharmaceuticals and other stocks. Vote "Outperform" if you believe SLRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SLRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel